{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:46:45Z","timestamp":1779119205194,"version":"3.51.4"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"21","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P50-NS057531"],"award-info":[{"award-number":["P50-NS057531"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["NS28840"],"award-info":[{"award-number":["NS28840"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R37 CA72614"],"award-info":[{"award-number":["R37 CA72614"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA111754"],"award-info":[{"award-number":["R01 CA111754"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01 NS055849"],"award-info":[{"award-number":["U01 NS055849"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30 CA082103"],"award-info":[{"award-number":["P30 CA082103"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA173085"],"award-info":[{"award-number":["R01 CA173085"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","award":["W81XWH-12-1-0157"],"award-info":[{"award-number":["W81XWH-12-1-0157"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","award":["W81XWH-13-1-0044"],"award-info":[{"award-number":["W81XWH-13-1-0044"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Preclinical studies using genetically engineered mouse models (GEMM) have the potential to expedite the development of effective new therapies; however, they are not routinely integrated into drug development pipelines. GEMMs may be particularly valuable for investigating treatments for less common cancers, which frequently lack alternative faithful models. Here, we describe a multicenter cooperative group that has successfully leveraged the expertise and resources from philanthropic foundations, academia, and industry to advance therapeutic discovery and translation using GEMMs as a preclinical platform. This effort, known as the Neurofibromatosis Preclinical Consortium (NFPC), was established to accelerate new treatments for tumors associated with neurofibromatosis type 1 (NF1). At its inception, there were no effective treatments for NF1 and few promising approaches on the horizon. Since 2008, participating laboratories have conducted 95 preclinical trials of 38 drugs or combinations through collaborations with 18 pharmaceutical companies. Importantly, these studies have identified 13 therapeutic targets, which have inspired 16 clinical trials. This review outlines the opportunities and challenges of building this type of consortium and highlights how it can accelerate clinical translation. We believe that this strategy of foundation\u2013academic\u2013industry partnering is generally applicable to many diseases and has the potential to markedly improve the success of therapeutic development. Cancer Res; 77(21); 5706\u201311. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-17-1789","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T01:10:38Z","timestamp":1507597838000},"page":"5706-5711","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies"],"prefix":"10.1158","volume":"77","author":[{"given":"Oph\u00e9lia","family":"Maertens","sequence":"first","affiliation":[{"name":"1Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Ludwig Center at Dana-Farber\/Harvard Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila E.","family":"McCurrach","sequence":"additional","affiliation":[{"name":"4Children's Tumor Foundation, New York, New York."},{"name":"5NYU Langone Medical Center, School of Medicine, New York University, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin S.","family":"Braun","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"De Raedt","sequence":"additional","affiliation":[{"name":"1Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inbal","family":"Epstein","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tannie Q.","family":"Huang","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer O.","family":"Lauchle","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California."},{"name":"7Genentech, South San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyerim","family":"Lee","sequence":"additional","affiliation":[{"name":"4Children's Tumor Foundation, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"8Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Dept. of Pediatrics, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Cripe","sequence":"additional","affiliation":[{"name":"9Nationwide Children's Hospital, Hematology & Oncology, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Wade","family":"Clapp","sequence":"additional","affiliation":[{"name":"10Herman Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Ratner","sequence":"additional","affiliation":[{"name":"8Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Dept. of Pediatrics, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Shannon","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Cichowski","sequence":"additional","affiliation":[{"name":"1Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Ludwig Center at Dana-Farber\/Harvard Cancer Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"2022061706364451800_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/477526a","article-title":"Translational research: 4 ways to fix the clinical trial","volume":"477","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"2022061706364451800_bib2","volume-title":"Neurofibromatosis: phenotype, natural history, and pathogenesis","author":"Riccardi","year":"1992"},{"key":"2022061706364451800_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2014.04.002","article-title":"An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer","volume":"55","author":"Maertens","year":"2014","journal-title":"Adv Biol Regul"},{"key":"2022061706364451800_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","article-title":"NF1 tumor suppressor gene function: narrowing the GAP","volume":"104","author":"Cichowski","year":"2001","journal-title":"Cell"},{"key":"2022061706364451800_bib5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.1068452","article-title":"Neurofibromas in NF1: Schwann cell origin and role of tumor environment","volume":"296","author":"Zhu","year":"2002","journal-title":"Science"},{"key":"2022061706364451800_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ccr.2007.12.027","article-title":"Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells","volume":"13","author":"Wu","year":"2008","journal-title":"Cancer Cell"},{"key":"2022061706364451800_bib7","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","article-title":"Mouse models of tumor development in neurofibromatosis type 1","volume":"286","author":"Cichowski","year":"1999","journal-title":"Science"},{"key":"2022061706364451800_bib8","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1126\/science.286.5447.2176","article-title":"Mouse tumor model for neurofibromatosis type 1","volume":"286","author":"Vogel","year":"1999","journal-title":"Science"},{"key":"2022061706364451800_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1073\/pnas.0307203101","article-title":"Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder","volume":"101","author":"Braun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706364451800_bib10","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2003-08-2650","article-title":"Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder","volume":"103","author":"Le","year":"2004","journal-title":"Blood"},{"key":"2022061706364451800_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature08279","article-title":"Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras","volume":"461","author":"Lauchle","year":"2009","journal-title":"Nature"},{"key":"2022061706364451800_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI63193","article-title":"Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice","volume":"123","author":"Chang","year":"2013","journal-title":"J Clin Invest"},{"key":"2022061706364451800_bib13","doi-asserted-by":"crossref","first-page":"76ra27","DOI":"10.1126\/scitranslmed.3001069","article-title":"A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice","volume":"3","author":"Lyubynska","year":"2011","journal-title":"Sci Transl Med"},{"key":"2022061706364451800_bib14","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/pbc.25546","article-title":"Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1","volume":"62","author":"Jousma","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2022061706364451800_bib15","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706364451800_bib16","first-page":"2014","article-title":"Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers","author":"Malone","journal-title":"Cancer Discov"},{"key":"2022061706364451800_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cub.2007.11.066","article-title":"TORC1 is essential for NF1-associated malignancies","volume":"18","author":"Johannessen","year":"2008","journal-title":"Curr Biol"},{"key":"2022061706364451800_bib18","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706364451800_bib19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/nou235","article-title":"Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study","volume":"17","author":"Weiss","year":"2015","journal-title":"Neuro-Oncol"},{"key":"2022061706364451800_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pbc.23015","article-title":"Preclincial testing of sorafenib and RAD001 in the Nf(flox\/flox);DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging","volume":"58","author":"Wu","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"2022061706364451800_bib21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ccr.2011.08.014","article-title":"Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors","volume":"20","author":"De Raedt","year":"2011","journal-title":"Cancer Cell"},{"key":"2022061706364451800_bib22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.celrep.2016.01.074","article-title":"Insertional Mutagenesis Identifies a STAT3\/Arid1b\/beta-catenin Pathway Driving Neurofibroma Initiation","volume":"14","author":"Wu","year":"2016","journal-title":"Cell Rep"},{"key":"2022061706364451800_bib23","first-page":"2014","article-title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies","author":"De Raedt","journal-title":"Nature"},{"key":"2022061706364451800_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2013 and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"key":"2022061706364451800_bib25","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022061706364451800_bib26","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI85183","article-title":"Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers","volume":"126","author":"Lock","year":"2016","journal-title":"J Clin Invest"},{"key":"2022061706364451800_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","article-title":"Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition","volume":"125","author":"Prada","year":"2013","journal-title":"Acta Neuropathol"},{"key":"2022061706364451800_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/onc.2012.579","article-title":"EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors","volume":"33","author":"Wu","year":"2014","journal-title":"Oncogene"},{"key":"2022061706364451800_bib29","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-12-1072","article-title":"Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target","volume":"18","author":"Patel","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022061706364451800_bib30","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1182\/blood-2008-04-155085","article-title":"Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+\/- mast cells","volume":"112","author":"McDaniel","year":"2008","journal-title":"Blood"},{"key":"2022061706364451800_bib31","doi-asserted-by":"crossref","unstructured":"Malone\u2008CF, Emerson\u2008C, Ingraham\u2008R, Barbosa\u2008W, Guerra\u2008S, Yoon\u2008H, et al\u2008mTOR and HDAC inhibitors converge on the TXNIP\/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors.Cancer Discov\u20082017 Sep 29. [Epub ahead of print]. doi: 10.1158\/2159-8290.CD-17-0177.","DOI":"10.1158\/2159-8290.CD-17-0177"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/21\/5706\/2933380\/5706.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/21\/5706\/2933380\/5706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T20:11:57Z","timestamp":1655496717000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/77\/21\/5706\/662455\/A-Collaborative-Model-for-Accelerating-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":31,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2017,10,31]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-17-1789","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,31]]}}}